Racial Disparities in MiT Family Translocation Renal Cell Carcinoma

Authors

Xiaofan Lu
Nassim Tawanaie Pour Sedehi
Xiaoping Su
Fangrong Yan
Omar Alhalabi
Nizar M Tannir
Gabriel G Malouf

Publication Date

11-2-2023

Journal

The Oncologist

Abstract

Racial disparities have been documented in the biology and outcome of certain renal cell carcinomas (RCCs) among Black patients. However, little is known about racial differences in MiT family translocation RCC (TRCC). To investigate this issue, we performed a case-control study using data from The Cancer Genome Atlas (TCGA) and the Chinese OrigiMed2020 cohort. A total of 676 patients with RCC (14 Asian, 113 Black, and 525 White) were identified in TCGA, and TRCC was defined as RCC with TFE3/TFEB translocation or TFEB amplification, leading to 21 patients with TRCC (2 Asian, 8 Black, 10 White, and 1 unknown). Asian (2 of 14 [14.3%] vs 10 of 525 [1.9%]; P = .036) and Black (8 of 113 [7.1%] vs 1.9%; P = .007) patients with RCC showed significantly higher prevalence of TRCC compared with White patients with RCC. The overall mortality rate of TRCC was slightly higher in Asian and Black patients compared with White patients (HR: 6.05, P = .069). OrigiMed2020 Chinese patients with RCC had a significantly higher proportion of TRCC with TFE3 fusions than TCGA White patients with RCC (13 of 250 [5.2%] vs 7 of 525 [1.3%]; P = .003). Black patients with TRCC were more likely to exhibit the proliferative subtype than White patients (6 of 8 [75%] vs 2 of 9 [22.2%]; P = .057) for those who had RNA-seq profiles. We present evidence of higher prevalence of TRCC in Asian and Black patients with RCC compared with White patients and show that these tumors in Asian and Black patients have distinct transcriptional signatures and are associated with poor outcomes.

Keywords

Humans, Carcinoma, Renal Cell, Kidney Neoplasms, Case-Control Studies, Basic Helix-Loop-Helix Leucine Zipper Transcription Factors, Translocation, Genetic, TFE3, TFEB, race, translocation renal cell carcinomas

DOI

10.1093/oncolo/oyad173

PMID

37315151

PMCID

PMC10628562

PubMedCentral® Posted Date

6-14-2023

PubMedCentral® Full Text Version

Post-print

Published Open-Access

yes